A carregar...
Patients with ROS1 rearrangement‐positive non‐small‐cell lung cancer benefit from pemetrexed‐based chemotherapy
ROS1 gene‐rearrangement in non‐small‐cell lung cancer (NSCLC) patients has recently been identified as a driver gene and benefited from crizotinib treatment. However, no data are available for ROS1‐positive NSCLC about chemotherapeutic options and prognostic data. We investigated pemetrexed‐based tr...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5083720/ https://ncbi.nlm.nih.gov/pubmed/27544536 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.809 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|